The attorneys at Morningstar Law Group are leaders who are frequently asked to share their legal insights and expertise. Here is a sampling of the wisdom our attorneys are sharing at industry conferences, in published articles, and at continuing legal education events.
Morningstar Law Group's Richard Caira Contributes to Financial Times Article on Data Regulation
March 11, 2021
Richard Caira, a partner in our firm’s Intellectual Property and Technology practice group, was recently interviewed by Financial Times for their article on the increasing demand for legal services, both advisory and litigation, brought about by the growing regulations on data privacy. Richard was well positioned to contribute having over 20 years of experience advising […]
Morningstar Law Group's Mack Paul Looks at 2021
March 11, 2021
Mack Paul, a partner in our firm’s Real Estate and Land Use practice group, joined two other local business leaders in an interview with Triangle Business Journal (TBJ) regarding their business outlook for 2021. Asked “Based on the information you have now, how do you see your company performing in 2021? What do you think […]
COVID-19 and Privacy: Can We Remain Anonymous?
May 20, 2020
The unprecedented spread of the COVID-19 coronavirus has alarmed policymakers and healthcare professionals alike. The rate at which infections continue to spike and the fact that most cases appear to be asymptomatic makes efforts to control the outbreak much more difficult as compared to other diseases. Certain mitigation efforts taken by governments around the world, […]
Time to Panic? The Effects of COVID-19 on the Internet.
April 16, 2020
Given the social distancing guidelines and broad stay-at-home orders necessitated by the global COVID-19 Coronavirus pandemic, organizations and schools around the world have been forced to reevaluate the way they conduct their day-to-day operations. As a result, those organizations and schools have shifted to telecommuting and remote learning, which has placed a major strain on […]
Safeguard Your IP
July 24, 2015
Biotechnology and pharmaceutical companies often engage contract CMOs to assist with the development of their drugs. This type of arrangement naturally involves the development of intellectual property (IP), so it is important for both the CMO and the sponsor to identify pre-existing intellectual property and also define how rights to new IP will be allocated, […]